Intensity Therapeutics Inc. Common stock (INTS)

FairStock Score: 43/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for understandable businesses with durable economics, honest accounting, and a price that leaves room for error. Intensity Therapeutics is not that today. It is a five-employee clinical-stage biotech, incorporated in 2012, with no reported revenue in the periods shown. Its lead candidate, INT230-6, is in Phase 3 for soft-tissue sarcoma and Phase 2 for neoadjuvant and metastatic triple-negative breast cancer. That is a high-risk scientific endeavor, not a proven commercial franchise, and I see no durable competitive moat from the facts provided. Financial health is poor. In fiscal 2025, ended 2025-12-31, it reported a net loss of $11.6M and diluted EPS of -$8.56. The quarter ended 2026-03-31 showed a net loss of $2.4M and diluted EPS of -$0.96; the quarter ended 2026-06-30 showed a net loss of $3.0M and diluted EPS of -$1.11. Trailing free cash flow is -$9.0M, a -77.3% yield on the $11.6M market cap, while FairStock's Altman Z-Score is -6.24 and Piotroski F-Score is 2/9. Return metrics are deeply negative: ROE -195.88% and ROCE -89.91%. The D/E of 0.01 is a small comfort, but cash burn is the real risk. At $3.55 on 2026-10-13, FairStock's calculated P/B is 1.13 and P/E is -1.77; a negative multiple means profits are absent, not that the stock is statistically cheap. The 52-week range of $3.10-$43.50 and beta of 3.03 show extreme volatility. FairStock score is 43/100, and its Lynch category is none because the company lost money in each of the last four years. Until trial data and financing clarify survival, this is speculation, not margin of safety.

In plain English: Intensity Therapeutics is a tiny company testing experimental cancer drugs, with only 5 employees. It has no reported revenue and loses millions of dollars, while burning cash, so the business looks weak today. The share price is far below its 52-week high, but with no profits it is hard to call the stock clearly cheap or expensive; it mostly reflects hope about its medical trials.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer